Cubist Systematic Strategies LLC increased its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 5.3% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 7,662 shares of the company’s stock after purchasing an additional 384 shares during the period. Cubist Systematic Strategies LLC’s holdings in IDEXX Laboratories were worth $1,191,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Point72 Asset Management L.P. purchased a new stake in IDEXX Laboratories during the 3rd quarter worth about $23,806,000. Zions Bancorporation bought a new position in IDEXX Laboratories in the 3rd quarter worth about $162,000. Asset Management One Co. Ltd. increased its stake in IDEXX Laboratories by 2.1% in the 3rd quarter. Asset Management One Co. Ltd. now owns 143,734 shares of the company’s stock worth $22,339,000 after acquiring an additional 2,977 shares during the last quarter. Allianz Asset Management GmbH increased its stake in IDEXX Laboratories by 27.8% in the 3rd quarter. Allianz Asset Management GmbH now owns 179,479 shares of the company’s stock worth $27,908,000 after acquiring an additional 39,016 shares during the last quarter. Finally, Nomura Asset Management Co. Ltd. increased its stake in IDEXX Laboratories by 6.3% in the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 11,986 shares of the company’s stock worth $1,864,000 after acquiring an additional 707 shares during the last quarter. 86.80% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories, Inc. (IDXX) opened at $157.30 on Tuesday. The firm has a market capitalization of $13,658.50, a PE ratio of 52.73, a price-to-earnings-growth ratio of 2.37 and a beta of 0.42. The company has a quick ratio of 0.77, a current ratio of 0.95 and a debt-to-equity ratio of -12.48. IDEXX Laboratories, Inc. has a one year low of $113.92 and a one year high of $173.01.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, October 31st. The company reported $0.79 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.05. The business had revenue of $492.00 million for the quarter, compared to analyst estimates of $492.94 million. IDEXX Laboratories had a negative return on equity of 336.64% and a net margin of 14.55%. The company’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same period in the prior year, the company earned $0.62 EPS. equities analysts predict that IDEXX Laboratories, Inc. will post 3.24 earnings per share for the current fiscal year.

IDXX has been the topic of a number of research analyst reports. Zacks Investment Research upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $184.00 target price on the stock in a research note on Tuesday, October 24th. Stifel Nicolaus restated a “buy” rating and issued a $185.00 target price on shares of IDEXX Laboratories in a research note on Tuesday, October 24th. Canaccord Genuity restated a “buy” rating and issued a $180.00 target price on shares of IDEXX Laboratories in a research note on Friday, October 6th. Bank of America upgraded IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 target price on the stock in a research note on Wednesday, August 23rd. Finally, BidaskClub lowered IDEXX Laboratories from a “hold” rating to a “sell” rating in a research note on Saturday. Three equities research analysts have rated the stock with a sell rating and five have assigned a buy rating to the stock. IDEXX Laboratories presently has an average rating of “Hold” and an average target price of $173.67.

In other news, Chairman Jonathan W. Ayers sold 54,000 shares of the stock in a transaction dated Tuesday, November 7th. The stock was sold at an average price of $151.32, for a total transaction of $8,171,280.00. Following the transaction, the chairman now directly owns 1,064,573 shares in the company, valued at approximately $161,091,186.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jonathan W. Ayers sold 18,000 shares of the stock in a transaction dated Friday, November 3rd. The shares were sold at an average price of $153.75, for a total value of $2,767,500.00. Following the transaction, the chief executive officer now owns 1,064,573 shares in the company, valued at $163,678,098.75. The disclosure for this sale can be found here. Insiders have sold a total of 110,000 shares of company stock worth $16,686,200 over the last quarter. Corporate insiders own 2.77% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Cubist Systematic Strategies LLC Buys 384 Shares of IDEXX Laboratories, Inc. (IDXX)” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this report can be read at https://www.watchlistnews.com/cubist-systematic-strategies-llc-buys-384-shares-of-idexx-laboratories-inc-idxx/1772375.html.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.